\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\:\\	on\\ the\\ scalp\\ there\\ were\\ numerous\\ 1\\-2\\ cm\\ subcutaneous\\ erythematous\\ nodules\\ with\\ overlying\\ partial\\ alopecia\\.\\ \ \(0\)\
\-\ laboratory\\:\\	hct\\ \\=\\ 32\\,\\ wbc\\ \\=\\ 7\\.2\\,\\ neuts\\ 9\\,\\ blasts\\ 10\\,\\ lymphs\\ 65\\,\\ plts\\ 50k\ \(0\)\
\-\ histopathology\\:\\ sections\\ demonstrated\\ a\\ dense\\,\\ diffuse\\ infiltrate\\ of\\ atypical\\ monomorphic\\ lymphoid\\ cells\\ that\\ replaced\\ much\\ of\\ the\\ dermis\\ and\\ subcutaneous\\ tissue\\.\\ immunophenotyping\\ of\\ cells\\ from\\ paraffin\\ block\\ revealed\\ a\\ t\\-cell\\ population\\.\\ flow\\ cytometry\\ demonstrated\\ this\\ population\\ to\\ be\\ cd2\\+\\,\\ cd3\\+\\,\\ cd4\\+\\,\\ cd8\\+\\,\\ c5\\+\\,\\ and\\ cd7\\+\\ as\\ well\\ as\\ cd10\\+\\.\\ these\\ findings\\ were\\ consistent\\ with\\ the\\ diagnosis\\ of\\ t\\-cell\\ lymphoblastic\\ leukemia\\,\\ group\\ 2\\.\ \(0\)\
\-\ the\\ patient\\ was\\ admitted\\ to\\ the\\ oncology\\ service\\ for\\ a\\ chemotherapy\\ regimen\\ to\\ include\\ cyclophosphamide\\,danorubicin\\,vincristine\\,prednisone\\,\\ l\\-asparaginase\\,\\ cytarabine\\,\\ 6\\-mp\\,\\ and\\ mtx\\.\\ the\\ scalp\\ nodules\\ resolved\\ after\\ the\\ second\\ course\\ of\\ chemotherapy\\.\\ he\\ is\\ currently\\ in\\ clinical\\ remission\\ undergoing\\ late\\ intensification\\.\ \(0\)\
\-\ all\\ t\\-cell\\ subtype\\ leukemia\\ cutis\\ \\(1997\\ uniformed\\ services\\ dermatology\\ seminar\\,\\ case\\#14\\)\\ submitted\\ by\\:\\ richard\\ laws\\,\\ cpt\\,\\ mc\\,\\ usa\ \(0\)\
\-\ presented\\ with\\ a\\ five\\ month\\ history\\ of\\ an\\ increasing\\ number\\ of\\ asymptomatic\\ scalp\\ nodules\\.\\ these\\ were\\ originally\\ diagnosed\\ as\\ bug\\ bites\\ by\\ his\\ primary\\ care\\ physician\\.\\ two\\ weeks\\ before\\ presenting\\ to\\ the\\ dermatology\\ clinic\\,\\ the\\ patient\\ had\\ a\\ cbc\\ as\\ part\\ of\\ gulf\\ war\\ veteran\\ screening\\ which\\ revealed\\ increased\\ lymphocytes\\ and\\ the\\ presence\\ of\\ blast\\ cells\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ t\\-cell\\:\\ 0\\.08178105089179981\ \(0\)\
\-\ scalp\\:\\ 0\\.05745874258812171\ \(0\)\
\-\ nodules\\:\\ 0\\.04217284363574704\ \(0\)\
\-\ cells\\:\\ 0\\.04079103207321425\ \(0\)\
\-\ dermatology\\:\\ 0\\.036593855591869305\ \(0\)\
\-\ \\=\\:\\ 0\\.035593532410160056\ \(0\)\
\-\ population\\:\\ 0\\.035387377756165926\ \(0\)\
\-\ subcutaneous\\:\\ 0\\.035286274376979974\ \(0\)\
\-\ neuts\\:\\ 0\\.034982215968121025\ \(0\)\
\-\ 50k\\:\\ 0\\.034982215968121025\ \(0\)\
\-\ monomorphic\\:\\ 0\\.034982215968121025\ \(0\)\
\-\ immunophenotyping\\:\\ 0\\.034982215968121025\ \(0\)\
\-\ cd2\\+\\:\\ 0\\.034982215968121025\ \(0\)\
\-\ cd3\\+\\:\\ 0\\.034982215968121025\ \(0\)\
\-\ c5\\+\\:\\ 0\\.034982215968121025\ \(0\)\
\-\ cd7\\+\\:\\ 0\\.034982215968121025\ \(0\)\
\-\ danorubicin\\:\\ 0\\.034982215968121025\ \(0\)\
\-\ cytarabine\\:\\ 0\\.034982215968121025\ \(0\)\
\-\ intensification\\:\\ 0\\.034982215968121025\ \(0\)\
\-\ laws\\:\\ 0\\.034982215968121025\ \(0\)\
\-\ veteran\\:\\ 0\\.034982215968121025\ \(0\)\
\-\ leukemia\\:\\ 0\\.0347992192470094\ \(0\)\
\-\ blasts\\:\\ 0\\.03223163191827997\ \(0\)\
\-\ paraffin\\:\\ 0\\.03223163191827997\ \(0\)\
\-\ cd8\\+\\:\\ 0\\.03223163191827997\ \(0\)\
\-\ cd10\\+\\:\\ 0\\.03223163191827997\ \(0\)\
\-\ l\\-asparaginase\\:\\ 0\\.03223163191827997\ \(0\)\
\-\ 6\\-mp\\:\\ 0\\.03223163191827997\ \(0\)\
\-\ mtx\\:\\ 0\\.03223163191827997\ \(0\)\
\-\ bug\\:\\ 0\\.03223163191827997\ \(0\)\
\-\ gulf\\:\\ 0\\.03223163191827997\ \(0\)\
\-\ cd4\\+\\:\\ 0\\.03062264339404122\ \(0\)\
\-\ cutis\\:\\ 0\\.03062264339404122\ \(0\)\
\-\ bites\\:\\ 0\\.03062264339404122\ \(0\)\
\-\ richard\\:\\ 0\\.029481047868438918\ \(0\)\
\-\ war\\:\\ 0\\.029481047868438918\ \(0\)\
\-\ lymphs\\:\\ 0\\.028595557585446022\ \(0\)\
\-\ alopecia\\:\\ 0\\.02787205934420017\ \(0\)\
\-\ 7\\.2\\:\\ 0\\.02787205934420017\ \(0\)\
\-\ lymphoblastic\\:\\ 0\\.02787205934420017\ \(0\)\
\-\ cpt\\:\\ 0\\.02787205934420017\ \(0\)\
\-\ cytometry\\:\\ 0\\.027260350297266606\ \(0\)\
\-\ plts\\:\\ 0\\.026730463818597863\ \(0\)\
\-\ \\,\\:\\ 0\\.025781911001646417\ \(0\)\
\-\ cyclophosphamide\\:\\ 0\\.02450976624742555\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.024309093532864007\ \(0\)\
\-\ lymphoid\\:\\ 0\\.02397987976875681\ \(0\)\
\-\ remission\\:\\ 0\\.02397987976875681\ \(0\)\
\-\ usa\\:\\ 0\\.02351248677012037\ \(0\)\
\-\ blast\\:\\ 0\\.023297934304762135\ \(0\)\
\-\ were\\:\\ 0\\.023098646865356204\ \(0\)\
\-\ vincristine\\:\\ 0\\.022900777723186803\ \(0\)\
\-\ subtype\\:\\ 0\\.022900777723186803\ \(0\)\
\-\ sections\\:\\ 0\\.022539778603322812\ \(0\)\
\-\ replaced\\:\\ 0\\.02190349824588162\ \(0\)\
\-\ block\\:\\ 0\\.02190349824588162\ \(0\)\
\-\ lymphocytes\\:\\ 0\\.02190349824588162\ \(0\)\
\-\ revealed\\:\\ 0\\.02176566579258804\ \(0\)\
\-\ dermis\\:\\ 0\\.0217591821975845\ \(0\)\
\-\ oncology\\:\\ 0\\.021619930928492157\ \(0\)\
\-\ regimen\\:\\ 0\\.02122929571891576\ \(0\)\
\-\ as\\:\\ 0\\.020517103268160756\ \(0\)\
\-\ infiltrate\\:\\ 0\\.02015019367334575\ \(0\)\
\-\ prednisone\\:\\ 0\\.02005681868362276\ \(0\)\
\-\ submitted\\:\\ 0\\.02005681868362276\ \(0\)\
\-\ demonstrated\\:\\ 0\\.01990015859092831\ \(0\)\
\-\ mc\\:\\ 0\\.019876412437286422\ \(0\)\
\-\ erythematous\\:\\ 0\\.019703852469271584\ \(0\)\
\-\ service\\:\\ 0\\.019620307194677014\ \(0\)\
\-\ 1\\-2\\:\\ 0\\.019458315152929968\ \(0\)\
\-\ originally\\:\\ 0\\.01915291419604057\ \(0\)\
\-\ 1997\\:\\ 0\\.019008598147743447\ \(0\)\
\-\ histopathology\\:\\ 0\\.01893836173068233\ \(0\)\
\-\ seminar\\:\\ 0\\.018869346878651105\ \(0\)\
\-\ uniformed\\:\\ 0\\.018669224443623757\ \(0\)\
\-\ hct\\:\\ 0\\.018417187119328812\ \(0\)\
\-\ services\\:\\ 0\\.018296927795934653\ \(0\)\
\-\ \\:\\:\\ 0\\.01794087009508992\ \(0\)\
\-\ these\\:\\ 0\\.017649561047284445\ \(0\)\
\-\ group\\:\\ 0\\.017643137188489987\ \(0\)\
\-\ late\\:\\ 0\\.017643137188489987\ \(0\)\
\-\ 32\\:\\ 0\\.016911275922087132\ \(0\)\
\-\ five\\:\\ 0\\.016911275922087132\ \(0\)\
\-\ number\\:\\ 0\\.016911275922087132\ \(0\)\
\-\ undergoing\\:\\ 0\\.016629149248738994\ \(0\)\
\-\ 65\\:\\ 0\\.016552093352480656\ \(0\)\
\-\ resolved\\:\\ 0\\.016439244402795997\ \(0\)\
\-\ part\\:\\ 0\\.016439244402795997\ \(0\)\
\-\ dense\\:\\ 0\\.01601744020180543\ \(0\)\
\-\ physician\\:\\ 0\\.015984232861843063\ \(0\)\
\-\ much\\:\\ 0\\.01569724610954296\ \(0\)\
\-\ overlying\\:\\ 0\\.015344279895191784\ \(0\)\
\-\ numerous\\:\\ 0\\.015205999215310165\ \(0\)\
\-\ clinic\\:\\ 0\\.015152008532549138\ \(0\)\
\-\ cbc\\:\\ 0\\.015152008532549138\ \(0\)\
\-\ 14\\:\\ 0\\.01494310482824191\ \(0\)\
\-\ atypical\\:\\ 0\\.014696550141309345\ \(0\)\
\-\ admitted\\:\\ 0\\.014649025573663646\ \(0\)\
\-\ screening\\:\\ 0\\.014464422337017247\ \(0\)\
\-\ before\\:\\ 0\\.014353259494843939\ \(0\)\
\-\ 9\\:\\ 0\\.01401712180646234\ \(0\)\
\-\ increasing\\:\\ 0\\.01389806525763774\ \(0\)\
\-\ presenting\\:\\ 0\\.01382063345516321\ \(0\)\
\-\ partial\\:\\ 0\\.01356093540654264\ \(0\)\
\-\ currently\\:\\ 0\\.013437193631000226\ \(0\)\
\-\ \\#\\:\\ 0\\.013300343725955906\ \(0\)\
\-\ second\\:\\ 0\\.013024321171583246\ \(0\)\
\-\ course\\:\\ 0\\.012795759696252544\ \(0\)\
\-\ laboratory\\:\\ 0\\.012496395777198674\ \(0\)\
\-\ diagnosed\\:\\ 0\\.01246902839998018\ \(0\)\
\-\ wbc\\:\\ 0\\.012361408137205602\ \(0\)\
\-\ presence\\:\\ 0\\.01230867308911559\ \(0\)\
\-\ care\\:\\ 0\\.01223086169471727\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.011462668246016218\ \(0\)\
\-\ 10\\:\\ 0\\.01143104852518615\ \(0\)\
\-\ by\\:\\ 0\\.011292626216229165\ \(0\)\
\-\ flow\\:\\ 0\\.011206563003406809\ \(0\)\
\-\ 2\\.\\:\\ 0\\.010783508499207372\ \(0\)\
\-\ clinical\\:\\ 0\\.010433769047880969\ \(0\)\
\-\ diffuse\\:\\ 0\\.010265902461806805\ \(0\)\
\-\ month\\:\\ 0\\.010173073574605592\ \(0\)\
\-\ primary\\:\\ 0\\.010045175646411494\ \(0\)\
\-\ his\\:\\ 0\\.009773369157329095\ \(0\)\
\-\ two\\:\\ 0\\.009711631895301609\ \(0\)\
\-\ weeks\\:\\ 0\\.009624118082941065\ \(0\)\
\-\ all\\:\\ 0\\.009590966227901947\ \(0\)\
\-\ include\\:\\ 0\\.009512513841390026\ \(0\)\
\-\ he\\:\\ 0\\.00946106088108341\ \(0\)\
\-\ presented\\:\\ 0\\.009243482678660354\ \(0\)\
\-\ cm\\:\\ 0\\.009095063959591212\ \(0\)\
\-\ physical\\:\\ 0\\.008319465355481104\ \(0\)\
\-\ consistent\\:\\ 0\\.008314675669965091\ \(0\)\
\-\ increased\\:\\ 0\\.008295574530951014\ \(0\)\
\-\ tissue\\:\\ 0\\.008037385668462673\ \(0\)\
\-\ a\\:\\ 0\\.00786904368687701\ \(0\)\
\-\ diagnosis\\:\\ 0\\.007786584645954046\ \(0\)\
\-\ well\\:\\ 0\\.007670956162574011\ \(0\)\
\-\ exam\\:\\ 0\\.007449341031545786\ \(0\)\
\-\ case\\:\\ 0\\.007418668384393931\ \(0\)\
\-\ had\\:\\ 0\\.0073168643620663025\ \(0\)\
\-\ findings\\:\\ 0\\.007217606888055395\ \(0\)\
\-\ after\\:\\ 0\\.007015877788131755\ \(0\)\
\-\ patient\\:\\ 0\\.006798348658066571\ \(0\)\
\-\ to\\:\\ 0\\.006778858864174384\ \(0\)\
\-\ which\\:\\ 0\\.006329938838264082\ \(0\)\
\-\ that\\:\\ 0\\.0058570663831699335\ \(0\)\
\-\ the\\:\\ 0\\.005486082726334357\ \(0\)\
\-\ be\\:\\ 0\\.005229193346602893\ \(0\)\
\-\ there\\:\\ 0\\.005046490303432494\ \(0\)\
\-\ from\\:\\ 0\\.005025538544262747\ \(0\)\
\-\ an\\:\\ 0\\.0046891462868441655\ \(0\)\
\-\ history\\:\\ 0\\.004683391022647156\ \(0\)\
\-\ of\\:\\ 0\\.004160850028499586\ \(0\)\
\-\ was\\:\\ 0\\.003921736199260662\ \(0\)\
\-\ this\\:\\ 0\\.003814036560770369\ \(0\)\
\-\ for\\:\\ 0\\.002893286304137758\ \(0\)\
\-\ on\\:\\ 0\\.0028725833824024922\ \(0\)\
\-\ \\(\\:\\ 0\\.002866514786681986\ \(0\)\
\-\ and\\:\\ 0\\.0028572858052733087\ \(0\)\
\-\ \\)\\:\\ 0\\.002831498778227401\ \(0\)\
\-\ is\\:\\ 0\\.0022313126126378\ \(0\)\
\-\ in\\:\\ 0\\.0016722112307152972\ \(0\)\
\-\ \\.\\:\\ 0\\.0014087117498946934\ \(0\)\
\-\ with\\:\\ 0\\.0013929068582129729\ \(0\)\
